Antibody Drug Conjugates (ADCs) Analysis

Antibody-drug conjugates (ADCs) are a class of biopharmaceutical medications created as a targeted therapy for treating cancer monoclonal antibodies bonded chemically to a drug molecule. The monoclonal antibody binds to particular proteins or receptors through linkers that kill specific cell types, such as cancer cells. The associated drug enters these cells, kills them, and leaves the rest of the cells alone. ADCs are complex molecules of antibodies bound to a biologically active cytotoxic payload (anticancer) or drug. ADCs, which distinguish between healthy and diseased tissue, combine the targeting abilities of monoclonal antibodies with the cancer-curing properties of cytotoxic drugs. Antibody-drug conjugates (ADCs) need to be characterized by Drug-to-antibody ratio (DAR) using UV/VIS spectroscopy. Other characterizations can be done using various structural and biophysical instruments.